Abstracts

Similar or Higher Memory Responses to Influenza Vaccination in Aviremic HIV-infected Patients on Antiretroviral Therapy

Background: Potential for recovery of antigen (Ag)-specific B cell functioning after long-term antiretroviral therapy (ART) in HIV-infected patients is not fully understood. Methods: We examined Ag-specific B cell responses to influenza (flu) vaccine in a cohort of 17 healthy controls and 28 ART-treated aviremic HIV+ patients who received vaccines last year and this year. Blood…

Sequential SHIV-Env Clones With Neutralization Sensitivity for Breadth Development

Background: Neutralizing antibodies gradually increase in breadth in selected SHIV-infected rhesus macaques (RMs) and HIV-1-infected humans. However, the envelope (Env) clones that are responsible for the development of neutralization breadth have not been identified. Methods: Because the SHIV-RM is the best available animal model for HIV-1 antibody studies, we screened 13 viremic RMs that were…

Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes

Background: The isolation of broadly neutralizing HIV-1 monoclonal antibodies (mAb) to distinct epitopes on the viral envelope glycoprotein (Env) provides the potential to use combinations of mAbs for prevention and treatment of HIV-1 infection. The potency and breadth of mAb combinations have not been well characterized. Methods: Two sets of combiantions were tested for neutralization…

Improved Antibody Cross-Neutralizing Activity in HIV-1 Dual-Infected LTNP Patients

Background: HIV-1 infected individuals, classified as long-term non-progressors (LTNP), remain healthy for many years in absence of antiretroviral therapy, with stable CD4+ T lymphocyte counts and low levels of viral replication. Neutralization studies in sera from LTNPs with undetectable viremia, showed little neutralizing activity (Nab) because of a reduced antigenic stimulation of B cells. A…

Phenotypic Neutralization Sieve Analysis of an SIV Nonhuman Primate Vaccine Challenge Study

Background: We previously characterized the neutralization sensitivity of the nonhuman primate (NHP) challenge stock SIVsmE660 and found the isolate was generally highly neutralization sensitive with a minor population of resistant variants (Lopker et al., J Virol 2013). We hypothesized that incomplete vaccine-mediated protection may result from protection against only the neutralization sensitive fraction of SIVsmE660.…